{
Matthew Weston

People

}
001122334455554433221100
001122334455554433221100

Deutsche Bank raises Novartis price target amid Pluvicto optimism

Deutsche Bank has raised its price target for Novartis shares to CHF115 from CHF110, maintaining a Buy rating, driven by optimism surrounding the cancer treatment Pluvicto's label expansion. The company shows strong financial health with a 10.85% revenue growth and a gross profit margin of 75.22%. In contrast, UBS downgraded Novartis from Buy to Neutral, lowering the target to CHF104, citing concerns over upcoming patent expirations that may hinder growth.
Investing.com
Swiss Franc Novartis AG CHE USA Emmanuel Papadakis Matthew Weston Show more
Finance & Economy, Market Report
13:47 03.04.2025

ubs maintains buy rating for astrazeneca with target price of 14200 pence

UBS has maintained its "Buy" rating for Astrazeneca, setting a target price of 14,200 pence. Analyst Matthew Weston highlighted promising study results for the cholesterol-lowering drug AZD0780 presented at the US Cardiologists Congress.
boerse.de
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
Finance & Economy, Market Report
10:50 01.04.2025

ubs maintains buy rating for astrazeneca amid cautious study results

UBS has maintained a "Buy" rating for AstraZeneca with a target price of 14,200 pence. Analyst Matthew Weston advised caution regarding the Calypso study results for Enebo, a treatment for hypothyroidism, noting the absence of a "clinically significant" designation for the primary endpoint and lack of independent expert commentary, suggesting unmet competitive expectations.
boerse.de
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
Finance & Economy, Market Report
12:47 17.03.2025

ubs rates roche shares buy with target price of 338 francs

UBS AG has maintained a "Buy" rating on Roche shares with a target price of 338 francs, highlighting the company's partnership with Zealand Pharma for the obesity treatment Petrelintide. Analyst Matthew Weston noted Roche's commitment to expanding obesity treatment mechanisms, following its acquisition of a GLP1/GIP treatment. Roche shares rose 5.3% to CHF 312.10, indicating an 8.3% upside potential from the target price, with a 22.2% increase since the start of 2025.
finanzen.ch
Swiss Franc UBS AG Zealand Pharma A/S Hoffmann-La Roche AG CHE Matthew Weston Show more
Finance & Economy, Market Report
17:03 14.03.2025

ubs lowers merck price target but maintains buy rating

UBS AG has downgraded its price target for Merck KGaA from €190 to €180 while maintaining a "Buy" rating. Following this analysis, Merck's share price fell by 4.1% to €135.50, reflecting a 32.84% upside potential relative to the new target. Year-to-date, the stock has decreased by 3.1%.
finanzen.net
Euro MERCK KGaA DEU CHE Matthew Weston
Finance & Economy, Market Report
18:57 07.03.2025

UBS maintains buy rating on Merck despite lowering price target to 180 euros

UBS has maintained a "Buy" rating for Merck KGaA but reduced its target price from €190 to €180, citing cautious expectations for Electronics sales and Life Science margins. Following this announcement, Merck shares fell by 4.1% to €135.50, indicating a potential growth of 32.84% relative to the new target.
finanzen.ch
Euro MERCK KGaA UBS AG DEU CHE Matthew Weston
Finance & Economy, Market Report
13:26 07.03.2025

ubs lowers merck price target but maintains buy rating

UBS has reduced its price target for Merck KGaA from 190 to 180 euros while maintaining a "Buy" rating. Analyst Matthew Weston has adjusted his earnings estimates, reflecting a more cautious outlook for Electronics sales and the Life Science segment's margin.
boerse.de
Euro MERCK KGaA DEU Matthew Weston
Finance & Economy, Market Report
12:21 07.03.2025

ubs lowers merck target price but maintains buy rating

UBS AG has reduced its target price for Merck KGaA from €190 to €180 while maintaining a "Buy" rating. Analyst Matthew Weston has adjusted earnings estimates, anticipating more cautious Electronics sales and Life Science margins. Following this analysis, Merck shares dropped 4.1% to €135.50, reflecting a potential upside of 32.84% to the new target.
finanzen.at
Euro MERCK KGaA DEU CHE Matthew Weston
Finance & Economy, Market Report
12:13 07.03.2025

UBS maintains buy rating for Merck KGaA with target price of 190 euros

UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the company's solid quarterly results, which met market expectations. Analyst Matthew Weston noted that the outlook for 2025 aligns with consensus estimates. The current share price stands at 140.45 euros, reflecting a 2.52% increase.
finanzen.net
Euro MERCK KGaA UBS AG DEU CHE Matthew Weston
Finance & Economy, Market Report
14:44 06.03.2025

UBS maintains buy rating for Merck with target price of 190 euros

UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros after the company reported solid quarterly results. Following this analysis, Merck shares rose by 2.0% to EUR 139.90, indicating a potential upside of 35.81% compared to the target price.
finanzen.ch
Euro MERCK KGaA UBS AG DEU Matthew Weston
Finance & Economy, Market Report
10:43 06.03.2025
Trending
Subcategory
Industry Trends Corporate News Startups & Entrepreneurship Supply Chain Management Industry Mergers & Acquisitions Global Trade Developments Government Economic Policies Cryptocurrency Trends Financial Scams and Security Workplace Trends CEO Changes Venture Capital Investments Finance Mergers & Acquisitions Fintech Startups Consumer Protection Regulations Retail and Consumer Goods Market Analysis and Predictions Funding Rounds & Investments Emerging Startups Global Trade Policies
Countries:
USA IND CHN JPN VNM KOR NLD FRA HKG MAR ARE THA PAK MEX UKR RUS MLT CHE UZB GAB
Companies:
Apple Inc. Google Inc. NVIDIA Corporation Delhivery Limited Ecom Express Ltd. Alphabet Inc. OpenAI ERC USD Ciscom Corp. ERICSSON - CLASS B Physicswallah Ltd. Snap Inc. Tiktok USD Semiconductor Manufacturing International Corporation Hua Hong Semiconductor Ltd. Spotify Technology S.A. Dropbox, Inc. Vimeo, Inc. Adobe Inc. Airbnb, Inc. SpaceXCoin USD
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Vietnamese Đồng Russian Ruble South Korean Won Pakistani Rupee Algerian Dinar Australian Dollar Thai Baht New Taiwan Dollar
People:
Ilya Sutskever Peter Thiel Donald Trump Trixie Lohmirmand Andrew Ferguson Sheryl Sandberg Mark Zuckerberg Pavel Prass Eric Cox Drew Houston Olivia Nottebohm Trae Stephens Napoleon Ta Bob Mcgrew Alec Radford Mira Murati Sam Altman Patrick Collison Changpeng Zhao Niren Shah

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.